Tag: oncology
Eiffage begins work on the future oncology building within the Grand Parc Campus in Villejuif
By Alexandra Saintpierre Published on 10/23/2023 at 8:43 p.m. Photo credit © Eiffage (Boursier.com) — Eiffage through its…
AstraZeneca: Promising new data in oncology
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Eli Lilly: will share several results in oncology
(CercleFinance.com) – Eli Lilly announces the presentation of several studies at the congress of the European Society of Medical Oncology (ESMO) which will be held in Madrid from October 20…
Celyad Oncology announces the termination of its American Depositary Receipt program – 09/25/2023 at 10:01 p.m.
Mont-Saint-Guibert, Belgium, September 25, 2023, 10:01 p.m. CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces today that Citibank, NA, as depositary (“Citibank”),…
Amgen creates a network of oncology expertise to accelerate the diffusion of therapies
(AOF) – Amgen today announced the launch of Amgen Partners of Choice, a new network that brings together its oncology research experts and world-class specialists in eight research centers around…
Oncology: Maat Pharma announces the end of the construction of its Isère factory
(AOF) – MaaT Pharma has announced the end of the construction of a factory dedicated to microbiota-based medicines, in Saint-Quentin-Fallavier in Isère. The biotech, specialist in the development of microbiotherapies…
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights – 09/04/2023 at 10:00 PM
Mont-Saint-Guibert, Belgium, September 4, 2023, 10:00 p.m. CET, regulated information – Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”) today announces its financial results and recent developments business…
Celyad Oncology receives approximately EUR 9.8 million in private placement commitments from historical shareholders – 2023-08-24 22:00
Celyad Oncology SA (“Celyad” or the “Company”) announced today that it has obtained commitments from a subsidiary of Fortress Investment Group (such subsidiary, “Fortress”), Tolefi SA (“Tolefi”) and other historical…
Oncology: OSE Immunotherapeutics receives 1.5 million euros from Bpifrance – 06/20/2023 at 18:07
(AOF) – OSE Immunotherapeutics announces today that it has received non-dilutive funding of 1.5 million euros from Bpifrance. The “R&D Innovation Loan” program aims to support the development of a…
Celyad Oncology: cash of 9.3 million euros at the end of March – 05/05/2023 at 16:45
(AOF) – Celyad Oncology announces that as of March 31, 2023, it had cash and cash equivalents of 9.3 million euros. Net cash consumption during the first quarter of 2023…
Celyad Oncology Reports 2022 Financial Results and Recent Highlights – 03/23/2023 at 22:01
Mont-Saint-Guibert, Belgium – Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell (CAR-T) therapies , today announces its financial…
Celyad Oncology will soon announce its 2022 operating and financial results and will hold a conference call – 03/17/2023 at 22:01
Mont-Saint-Guibert, Belgium – Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor T cell therapies…